This clinical trial is focused on studying a type of cancer called seminoma, specifically in its early stages, known as stage IIa/IIb, where the tumor is less than 3 cm in size. The study aims to evaluate a treatment approach that involves reducing the intensity of therapy. Initially, patients will receive one cycle of a combination of two chemotherapy drugs, etoposide and cisplatin. After three weeks, if a special scan called FDG-PET shows no signs of cancer, patients will either receive one cycle of another chemotherapy drug, carboplatin, or a focused dose of radiation therapy on the lymph nodes.
The purpose of this study is to assess how effective this reduced treatment approach is in delaying the return of cancer. The study will monitor patients over time to see how long they remain free of cancer. Additionally, the study will explore the relationship between a specific biomarker, miRNA-M371, and the response to treatment. This biomarker is a small molecule found in the blood that may help predict how well the treatment is working.
Participants in the study will undergo regular check-ups and tests to monitor their health and the status of their cancer. The study will also evaluate the overall safety of the treatment and its impact on the quality of life of the participants. The trial is expected to continue for several years to gather comprehensive data on the effectiveness and safety of the treatment approach.



France